Martin Auster
Stock Analyst at Raymond James
(2.72)
# 2,032
Out of 5,090 analysts
56
Total ratings
59.52%
Success rate
14.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $73.64 | -3.59% | 2 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Market Perform | n/a | $71.63 | - | 2 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $93.29 | +15.77% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $205.44 | +31.91% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $20.28 | +72.58% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $458.12 | -7.45% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $53.40 | +124.72% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $36.38 | +188.62% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $8.90 | +192.13% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $5.77 | +1,979.72% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $725 → $300 | $27.46 | +992.50% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $30.87 | +87.88% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $489.31 | -59.94% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.42 | +6,801.41% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $204.00 | -70.59% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $45.02 | +44.38% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $22.26 | +227.94% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.12 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $21.33 | +265.68% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.73 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $11.95 | +259.83% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $9.61 | +118.52% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $44.41 | -63.97% | 1 | May 7, 2020 |
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $73.64
Upside: -3.59%
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $71.63
Upside: -
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $93.29
Upside: +15.77%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $205.44
Upside: +31.91%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $20.28
Upside: +72.58%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $458.12
Upside: -7.45%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $53.40
Upside: +124.72%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $36.38
Upside: +188.62%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $8.90
Upside: +192.13%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.77
Upside: +1,979.72%
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $27.46
Upside: +992.50%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $30.87
Upside: +87.88%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $489.31
Upside: -59.94%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.42
Upside: +6,801.41%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $204.00
Upside: -70.59%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $45.02
Upside: +44.38%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $22.26
Upside: +227.94%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.12
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $21.33
Upside: +265.68%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.73
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $11.95
Upside: +259.83%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $9.61
Upside: +118.52%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $44.41
Upside: -63.97%